IL2 and hairy cell leukemia: Since the first immunotherapy cytokine interferon-α (IFNα) was approved by the U.S. Food and Drug Administration (FDA) in 1986 for hairy cell leukemia, early-stage cancer immunotherapy from cytokines to interleukin-2 (IL-2) has shown limited therapeutic effect with high toxicity [1,2].